Coordinatore | MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
Nazionalità Coordinatore | Austria [AT] |
Sito del progetto | http://www.gmsafoodproject.eu |
Totale costo | 3˙424˙810 € |
EC contributo | 2˙606˙622 € |
Programma | FP7-KBBE
Specific Programme "Cooperation": Food, Agriculture and Biotechnology |
Code Call | FP7-KBBE-2007-1 |
Funding Scheme | CP-FP |
Anno di inizio | 2008 |
Periodo (anno-mese-giorno) | 2008-08-01 - 2012-03-31 |
# | ||||
---|---|---|---|---|
1 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | coordinator | 0.00 |
2 |
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
Organization address
address: LIMESTONE AVENUE - CAMPBELL contact info |
AU (CANBERRA) | participant | 0.00 |
3 |
KOZPONTI KORNYEZET- ES ELELMISZER-TUDOMANYI KUTATOINTEZET
Organization address
address: HERMAN OTTO UT 15 contact info |
HU (BUDAPEST) | participant | 0.00 |
4 |
Nemzeti Agrarkutatasi es Innovacios Kozpont
Organization address
address: SZENT GYORGYI ALBERT UTCA 4 contact info |
HU (GODOLLO) | participant | 0.00 |
5 |
NORGES MILJO-OG BIOVITENSKAPLIGE UNIVERSITET
Organization address
address: UNIVERSITETSTUNET 3 contact info |
NO (AS) | participant | 0.00 |
6 |
NORGES VETERINAERHOGSKOLE
Organization address
address: Ullevaalsveien 72 contact info |
NO (OSLO) | participant | 0.00 |
7 |
TEAGASC - AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY
Organization address
address: Oak Park contact info |
IE (CARLOW) | participant | 0.00 |
8 |
TROYKA MAKINA GIDA INSAAT MUHENDISLIK ENERJI CEVRE BILISIM ARASTIRMA GELISTIRME DANISMANLIK SANAYI VE PAZARLAMA LIMITED SIRKETI
Organization address
address: ODTU TEKNOKENT IKIZLER BINASI contact info |
TR (ANKARA) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'The function of post market monitoring is to further assess possible nutritional and health effects of authorized GM foods on a mixed population of human and animal consumers. Currently, however, little is known about exposure levels, whether adverse effects are predictable, and the occurrence of any unexpected effects following market release of GM foods. Our objective is to identify a panel of anatomic, physiologic, biochemical, molecular, allergenic, and immunogenic biomarkers, which could be used to predict harmful GMO effects after product authorization. Using a prototype allergenic α-amylase inhibitor GM-pea, we will extrapolate multiple biomarker databases that correlate GMO effects during gestation, growth, maturation in various animal models with humans. We will establish biomarkers in GMO-fed pigs, salmon, rats, and mice, in addition to indirect effects of GM feeding in the food chain and GMO influence during an underlying allergic disorder. These experiments will yield data on general health with a specific focus on allergy and immunology. To extrapolate our data to humans, we will establish a comparative database with antigenic epitopes and antibody crossreactivity in legume allergic patients and human-mouse chimera in which a human immune system is transplanted into a mouse lacking an immune system. Taken together, these results will yield databases from multiple biological systems that will be used in a mathematical modeling strategy for biomarker discovery and validation. Our consortium consists of partners from Austria, Turkey, Hungary, Ireland, Norway, and Australia and constitutes a diverse interdisciplinary team from veterinary medicine, nutrition, agriculture, immunology, and medicine that is dedicated to the development and validation of biomarkers to be used for post market monitoring of animals and humans consuming newly authorized GMOs.'
Genetically modified (GM) foods have much to offer, but European researchers are keen to make sure developments in the field are safe and beneficial right along the food chain.